These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. A novel monoclonal antibody SMab-2 recognizes endogenous IDH2-R172S of chondrosarcoma. Liu X; Ogasawara S; Kaneko MK; Oki H; Hozumi Y; Goto K; Takagi M; Kato Y Biochem Biophys Res Commun; 2015 Apr; 459(4):636-42. PubMed ID: 25753205 [TBL] [Abstract][Full Text] [Related]
10. A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Kato Y; Jin G; Kuan CT; McLendon RE; Yan H; Bigner DD Biochem Biophys Res Commun; 2009 Dec; 390(3):547-51. PubMed ID: 19818334 [TBL] [Abstract][Full Text] [Related]
11. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690 [TBL] [Abstract][Full Text] [Related]
12. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma. Pusch S; Schweizer L; Beck AC; Lehmler JM; Weissert S; Balss J; Miller AK; von Deimling A Acta Neuropathol Commun; 2014 Feb; 2():19. PubMed ID: 24529257 [TBL] [Abstract][Full Text] [Related]
13. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors. Bleeker FE; Lamba S; Leenstra S; Troost D; Hulsebos T; Vandertop WP; Frattini M; Molinari F; Knowles M; Cerrato A; Rodolfo M; Scarpa A; Felicioni L; Buttitta F; Malatesta S; Marchetti A; Bardelli A Hum Mutat; 2009 Jan; 30(1):7-11. PubMed ID: 19117336 [TBL] [Abstract][Full Text] [Related]
14. Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation. Kato Y; Kaneko MK Biochem Biophys Res Commun; 2013 Apr; 433(4):374-8. PubMed ID: 23524262 [TBL] [Abstract][Full Text] [Related]
15. Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. Takano S; Kato Y; Yamamoto T; Kaneko MK; Ishikawa E; Tsujimoto Y; Matsuda M; Nakai K; Yanagiya R; Morita S; Tsuboi K; Matsumura A J Neurooncol; 2012 Jul; 108(3):361-73. PubMed ID: 22396072 [TBL] [Abstract][Full Text] [Related]
16. Investigating the Influence of Hotspot Mutations in Protein-Protein Interaction of IDH1 Homodimer Protein: A Computational Approach. Thirumal Kumar D; Sneha P; Uppin J; Usha S; George Priya Doss C Adv Protein Chem Struct Biol; 2018; 111():243-261. PubMed ID: 29459034 [TBL] [Abstract][Full Text] [Related]
17. Monoclonal antibody specific for IDH1 R132H mutation. Capper D; Zentgraf H; Balss J; Hartmann C; von Deimling A Acta Neuropathol; 2009 Nov; 118(5):599-601. PubMed ID: 19798509 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemistry using monoclonal antibody MsMab-2 is useful to detect IDH1 R132L in intrahepatic cholangiocarcinoma. Hayashi A; Misumi K; Shibahara J; Kokudo N; Kato Y; Fukayama M Pathol Int; 2016 Oct; 66(10):578-582. PubMed ID: 27595804 [TBL] [Abstract][Full Text] [Related]